Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion type Assertion NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_head.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion description "[COMBI-v was an open-label, randomised phase 3 study in which 704 patients with metastatic melanoma with a BRAF Val600 mutation were randomly assigned (1:1) by an interactive voice response system to receive either a combination of dabrafenib (150 mg twice-daily) and trametinib (2 mg once-daily) or vemurafenib monotherapy (960 mg twice-daily) orally as first-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_provenance.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion evidence source_evidence_literature NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_provenance.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion SIO_000772 26433819 NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_provenance.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion wasDerivedFrom befree-2016 NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_provenance.
- NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_assertion wasGeneratedBy ECO_0000203 NP1294668.RABVpm8S87UggQyg7-roIN3v1dWr8rsktpoae45vTPDbw130_provenance.